Remote Ischemic Conditioning in Patients With Ulcerative Colitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02445365|
Recruitment Status : Completed
First Posted : May 15, 2015
Last Update Posted : March 22, 2018
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD). At the time of diagnosis it is not possible to predict the course of the disease, which can range from a few flares in a lifetime to uncontrollable disease leading to hospitalization, surgery and stoma. There is a continuous need to improve treatment as well as diagnostic and prognostic tools.
This study evaluates the clinical efficacy, tolerability and feasibility of remote ischemic conditioning (RIC) in patients with moderate active ulcerative colitis (UC). The investigators hypothesize that RIC beyond the well known effect on reperfusion tissue damage has a clinically relevant anti-inflammatory effect in UC. RIC constitute a repeated brief and non-harmful suppression of blood circulation in a limb. The mechanism of action of RIC is likely to involve suppressed inflammation and cell death.
Our study is a randomized clinical controlled study including 38 patients. Patients will receive RIC or sham for 10 consecutive days.
The effect of RIC on active UC is evaluated by changes patient's symptoms, endoscopy findings, and various markers in the blood, faeces and the intestinal wall.
|Condition or disease||Intervention/treatment||Phase|
|Colitis, Ulcerative Gastrointestinal Diseases Pathologic Processes Intestinal Diseases Inflammatory Bowel Diseases||Device: AutoRIC device||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Effect of Remote Ischemic Conditioning (RIC) on Inflammation and Remodelling of Extracellular Matrix Proteins in Patients With Inflammatory Bowel Diseases|
|Study Start Date :||May 2015|
|Actual Primary Completion Date :||February 2018|
|Actual Study Completion Date :||February 15, 2018|
Experimental: Active RIC
Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
Device: AutoRIC device
Sham Comparator: Sham
As above with a cuff pressure of 20 mmHg
Device: AutoRIC device
- Change in index of clinical activity - numerical change in Mayo score including endoscopic subscore [ Time Frame: 10 days ]
- Change in fecal calprotectin. [ Time Frame: 10 days ]
- Change in endoscopy - central reading according to Mayo endoscopic subscore and UCEIS [ Time Frame: 10 days ]
- Number of patients achieving clinical remission (Mayo score <3) [ Time Frame: 10 days ]
- Patient experience of repeated RIC (questionnaire, including placebo recognition). [ Time Frame: 10 days ]
- Change in histological score of inflammation. [ Time Frame: 10 days ]
- Changes in serum and mucosal cytokine profile in particular Th1/Th2/Th9/Th17/Th22. measured by FlowCytomix Multiplex. [ Time Frame: 10 days ]
- Changes in serum markers of inflammation (serum C-reactive protein). [ Time Frame: 10 days ]
- Changes in serum markers of extracellular matrix proteins (C1M, C3M, C4M, P1NP and VICM). [ Time Frame: 10 days ]
- Changes in serum and mucosal level of CGRP, endothelin-1, endothelin-2. [ Time Frame: 10 days ]
- Effect of RIC in patients with active ulcerative colitis using the Langendorff model (to document activation of a cardioprotective response). [ Time Frame: 10 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02445365
|Odense University Hospital|
|Odense, Denmark, 5000|
|Study Chair:||Jens Kjeldsen, MD, PhD||Odense University Hospital|
|Principal Investigator:||Line Godskesen||Odense University Hospital|